Literature DB >> 2452773

An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.

V R Zurawski1, R C Knapp, N Einhorn, P Kenemans, R Mortel, K Ohmi, R C Bast, R E Ritts, G Malkasian.   

Abstract

Preoperative serum CA 125 levels were determined for 36 patients with Stage I and II ovarian carcinoma. Levels ranged from 9 to 1962 U/ml with a mean of 216 U/ml. In Stage I patients, CA 125 levels averaged 133 U/ml and in Stage II patients 382 U/ml. Nine of 24 Stage I (38%) and 9 of 12 Stage II patients (75%) had CA 125 levels in excess of 65 U/ml in a population somewhat overrepresented in mucinous tumors. Patients with non-mucinous neoplasms had CA 125 elevations more often--in 75% of the cases--than those with mucinous tumors. A larger study will be required to more precisely estimate the fraction of early stage patients with elevated preoperative serum CA 125 levels; however, this investigation demonstrates an assay sensitivity minimally adequate to initiate a pilot evaluation of serum CA 125 levels in a population at risk for ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452773     DOI: 10.1016/0090-8258(88)90039-x

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  Combined use of biomarkers for detection of ovarian cancer in high-risk women.

Authors:  Martin Donach; Yinhua Yu; Grazia Artioli; Giuseppe Banna; Weiwei Feng; Robert C Bast; Zhen Zhang; Maria O Nicoletto
Journal:  Tumour Biol       Date:  2010-06

3.  HE4 combined with CA125: favorable screening tool for ovarian cancer.

Authors:  Nasrin Ghasemi; Samira Ghobadzadeh; Mahnaz Zahraei; Hemn Mohammadpour; Salahadin Bahrami; Mohammad Bakhshi Ganje; Shokoh Rajabi
Journal:  Med Oncol       Date:  2013-12-10       Impact factor: 3.064

4.  Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

Authors:  M W McIntosh; C Drescher; B Karlan; N Scholler; N Urban; K E Hellstrom; I Hellstrom
Journal:  Gynecol Oncol       Date:  2004-10       Impact factor: 5.482

5.  Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient.

Authors:  Pithi Chanvorachote; Sudjit Luanpitpong; Preedakorn Chunhacha; Worrawat Promden; Virote Sriuranpong
Journal:  Oncol Lett       Date:  2012-05-10       Impact factor: 2.967

6.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Authors:  Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien van Haaften-Day; Laura J Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven Skates; Daniel W Chan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2007-10-24       Impact factor: 5.482

Review 7.  Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI.

Authors:  Rosemarie Forstner
Journal:  Eur Radiol       Date:  2007-08-14       Impact factor: 5.315

8.  [Comparison of serum cancer antigen 125, human epididymis protein 4, ROMA, and CPH-I for diagnosis of ovarian cancer in Chinese patients with ovarian mass].

Authors:  Gong Shipeng; Chen Yongning; Zhang Yadi; L I Chanyuan; Jiang Qifan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-12-30

9.  HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm.

Authors:  T Van Gorp; I Cadron; E Despierre; A Daemen; K Leunen; F Amant; D Timmerman; B De Moor; I Vergote
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

10.  Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women.

Authors:  Hiroyuki Fujiwara; Mitsuaki Suzuki; Nobuhiro Takeshima; Ken Takizawa; Eizo Kimura; Toru Nakanishi; Kyosuke Yamada; Hirokuni Takano; Hiroshi Sasaki; Koji Koyama; Kazunori Ochiai
Journal:  Tumour Biol       Date:  2014-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.